Notably, anti-CCL2 antibody treatment attenuated lung fibrosis in these mice, suggesting that targeting M2 macrophages may represent a promising therapeutic strategy for treating fibrosis [19]. This evidence concerns the gene CCL2 and pulmonary fibrosis.